| ［1］ Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)［J］. J Thorac Oncol, 2014, 9(2): 154-162. DOI: 10.1097/JTO.0000000000000033. ［2］ Karachaliou N, Molina-Vila MA, Rosell R. The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer［J］. Expert Rev Respir Med, 2015, 9(3): 241-244. DOI: 10.1586/17476348.2015.1046439. ［3］ Watanabe S, Minegishi Y, Yoshizawa H, et al. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q［J］. J Thorac Oncol, 2014, 9(2): 189-194. DOI: 10.1097/JTO.0000000000000048. ［4］ Kobayashi Y, Mitsudomi T. Not all EGFR mutations in lung cancer are created equal: perspectives for individualized treatment strategy［J］. Cancer Sci, 2016, 107(9): 1179-1186. DOI: 10.1111/cas.12996. ［5］ Xu J, Jin B, Chu T, et al. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: a real-world study in China［J］. Lung Cancer, 2016, 96: 87-92. DOI: 10.1016/j.lungcan.2016.01.018. ［6］ Dungo RT, Keating GM. Afatinib: first global approval［J］. Drugs, 2013, 73(13): 1503-1515. DOI: 10.1007/s40265-013-0111-6. ［7］ Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUXLung 3: a phase Ⅲ study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations［J］. J Clin Oncol, 2013, 31(27): 3342-3350. DOI: 10.1200/JCO.2012.46.1764. ［8］ Banno E, Togashi Y, Nakamura Y, et al. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: what is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?［J］. Cancer Sci, 2016, 107(8): 1134-1140. DOI: 10.1111/cas.12980. ［9］ Ke EE, Wu YL. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutationpositive non-small cell lung cancer: a review of the clinical evidence［J］. Ther Adv Respir Dis, 2016, 10(3): 256264. DOI: 10.1177/1753465816634545. ［10］ Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined posthoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6［J］. Lancet Oncol, 2015, 16(7): 830-838. DOI: 10.1016/S1470-2045(15)00026-1. ［11］ Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase Ⅱ trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both［J］. J Clin Oncol, 2013, 31(27): 3335-3341. DOI: 10.1200/JCO.2012.45.0981. |
